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same size. As a ﬁrst step, regression analysis in the full sample
was performed, where VAS assessment (0–100) of actual health
state constituted the dependent variable and dichotomized (some
problem/considerable problem) answers on the ﬁve dimensions
the independent. After excluding outliers, (standardized [z-]
residuals <-2.5 or >2.5), ten pairs of analyses were performed,
excluding one part of the sample at the time. From the ﬁrst analy-
sis in each pair, outliers were excluded and the second analysis
was performed. The coefﬁcients gained in the second analysis
were used to calculate Jackknife estimates of “true” coefﬁcients.
RESULTS: The model estimated constant of 89.7 and coefﬁcients
for each dimension assessed as having “some problem” (self care:
-15.89; mobility: -10.30; usual activities: -9.52; depression: 
-7.87; pain/discomfort: -7.49) and for having “considerable
problem” with pain/discomfort: -6.00; usual activities: -8.09;
depression: -33.66 and on any of dimensions: -20.18. Interac-
tions did not increase explanatory value of the analysis. 
CONCLUSIONS: Based on this model, the most important
determinant of health status value (utility) for the Swedish pop-
ulation is depression, followed by problems with mobility and
self-care. Pain/discomfort is the least important, regardless of the
magnitude of the problems were assessed.
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OBJECTIVES: To assess to what extent QoL results obtained
through a generic instrument (EQ-5D) correlate with those cap-
tured by a disease-sensitive measure (QoL-Assessment of Growth
Hormone Deﬁciency in Adults). METHODS: Data were col-
lected through a mailing survey to a random sample (n = 2990)
of the Swedish population. The questionnaire comprised EQ-5D
and QoL-AGHDA. QoL-AGHDA is a 25-item measure that
elicits yes/no responses to personal statements describing prob-
lems that characterize aspects of HrQoL in growth hormone deﬁ-
ciency. A high QoL-AGHDA score denotes poor HrQoL. EQ-5D
is a well-known and widely recognized generic instrument.
(EuroQoL Group, 1990). The response rate was 65% and com-
plete data on EQ-5D and QoL-AGHDA were obtained from
1665 (48.2% males; mean age 49.5, range 18–85 years) respon-
dents. RESULTS: For EQ-5D dimensions: 11% respondents
reported problems with mobility, 2% with self care, 9% usual
activities, 46% pain/discomfort and 30% anxiety/depression. All
results were weighted to represent the Swedish population proﬁle
with respect to age and gender. The mean EQ-5D VAS score was
80 (SD 17.3) and the mean QoL-AGHDA score was 3.9 (SD
4.8). There was a signiﬁcant correlation between QoL-AGHDA
scores and EQ-5D VAS (r = -0.56, p < 0.001). CONCLUSIONS:
These results show that there is strong correlation between
results generated by a disease-sensitive and a generic measure,
and thus suggest that using generic instruments for QoL assess-
ments in speciﬁc conditions yield reliable results that could be
employed for pharmacoeconomic evaluations.
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OBJECTIVES: Measuring the cost-effectiveness of interventions
for adult growth hormone deﬁciency (AGHD) requires estimates
of the beneﬁts. For the purposes of cost-utility analysis those ben-
eﬁts should be expressed as QALYs. Where primary outcomes
data are collected using condition-sensitive measures of health-
related quality of life (HrQoL) then recalibration is necessary.
This paper reports the use of EQ-5D as a mechanism for con-
verting such data into a useable QALY metric. METHODS:
QoL-AGHDA is a 25-item questionnaire designed for use in
AGHD. Yes/no responses are used to compute a summary index
with a high score denoting poor HrQoL. A total of 1000 indi-
viduals randomly selected from the UK Population Preference
Panel were sent a copy of QoL-AGHDA together with EQ-5D,
a widely used generic measure of HrQoL calibrated in terms of
TTO preference weights. Corresponding QoL-AGHDA data on
patients (n = 836) was made available from UK KIMS (Pﬁzer
International Metabolic Database). RESULTS: Completed
survey forms were received from 882 individuals (57% female,
median age 55). There was a high degree of correlation between
EQ-5D and QOL-AGHDA summary score (r = -0.529, p <
0.001). Age/gender standardised mean EQ-5D index scores were
computed for different categories of QoL-AGHDA score in the
general population survey. These were used as a lookup table to
provide estimates of EQ-5D for each patient in the KIMS dataset
according to their age/gender and QoL-AGHDA score. Within-
year QALY losses between the EQ-5D index for KIMS patients
and corresponding EQ-5D for the general population. Using 
age-speciﬁc prevalence data together with the relevant popula-
tion life expectancy tables, it was also possible to estimate poten-
tial lifetime QALY losses for GHD. CONCLUSIONS: AGHD
patients record lower levels of HrQoL than the general popula-
tion. This difference equates to a 0.15 QALY “loss” per annum
and a lifetime loss across all GHD patients of some 40,000
QALYs.
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There is conﬂicting evidence about whether reduced height
results in ill health. OBJECTIVE: The objective of this study was
to determine if there exists an association between height and
health-related utility (EQ5Dindex). METHODS: This was a retro-
spective study of two large health data sources that recorded
height and other anthropomorphic parameters along with the
EQ5Dindex. The ﬁrst a national survey in the general population
(English Health Survey, 1996), the second an ongoing study to
characterise outcome in hospital treated patients (the Health
Outcomes Data Repository [HODaR]). Both of these sources
had large numbers of observations, thus dealing with the wide
variability in factors leading to ill health potentially confound-
ing or masking any association. RESULTS: There was a direct
association between height and the EQ5Dindex. This association
was logarithmic; the gradient was more marked in shorter 
subjects. The association was signiﬁcant. On average, a 10cm
increase in height resulted in 0.01 more EQ5Dindex units in men
and 0.02 in women (standardized for age and ethnicity). This
association appeared to be independent of confounding factors
such as body mass, where shorter people had in all BMI cate-
gories lower health utility than taller people. An increase in
height from the ninth centile to the eighth equated to a utility
gain of 0.021 in men and 0.025 in women. A shift from the third
centile to the second equated to a utility gain of 0.007 in men
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and 0.006 in women. CONCLUSION: There was an association
between height and health-related utility. The determinants of
this association are not as yet clear and are likely to be complex
involving social, environmental and other factors. Treatments
are available to increase the height of children with short stature.
This analysis suggests that these treatments would be cost effec-
tive depending upon effect and price.
HEMATOLOGICAL DISORDERS
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OBJECTIVE: To determine whether the administration of
epoetin alfa (rHuEPO) reduced the amount of blood transfusions
required by patients during surgical intensive care unit (SICU)
admission. METHODS: A retrospective cohort of all adult
patients admitted to the SICU of the LAC + USC Medical Center
between January, 2001 and December, 2003, who remained in
the SICU for at least ﬁve days. Patients who met entry criteria
were stratiﬁed into two groups based on whether rHuEPO was
administered. Series of T-tests were performed using variables
such as, demographics, laboratory data, monitoring parameters,
medication dosing, intervention histories, and mortality between
the groups to determine whether or not any differences existed
after stratiﬁcation. Multivariate stepwise logistic regression
analyses were conducted to determine the signiﬁcant covariates
which were associated with rHuEPO administration. Selection
bias was adjusted by matching subjects using propensity score
methods. RESULTS: The primary efﬁcacy end point was the
amount of packed red blood cells (PRBC) transfused per patient
after day-seven of SICU stay between rHuEPO and non-rHuEPO
groups. After matching for likelihood of receiving rHuEPO using
propensity scores method, rHuEPO patients received 900.1 
± 1678.2mL of PRBC after day-seven of SICU stay while non-
rHuEPO patients received 875.1 ± 1687.2mL of PRBC (p =
0.9165). There was no statistical difference in transfusion inde-
pendence between the number of patients in the matched groups
who received transfusions after day-seven of SICU stay (rHuEPO
47/100 (47%) vs. non-rHuEPO 51/100 (51%), p = 0.5715) or
for the last recorded hematocrit (Hct) values of SICU stay
(rHuEPO 30.3 ± 5.6mg/dL, non-rHuEPO 30.0 ± 3.5mg/dL, 
p = 0.5540). There also was no statistical difference between
matched groups for SICU mortality (rHuEPO 11/100 (11%),
non-rHuEPO 15/100 (15%), p = 0.4003). CONCLUSIONS: In
our cohort, administration of rHuEPO was not associated with
a difference in units of PRBC transfused, transfusion indepen-
dence, discharge Hct or SICU mortality.
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OBJECTIVES: The objective of this study was to determine
whether anemia contributes to the likelihood of experiencing an
in-hospital fall. METHODS: A retrospective case-control study
was conducted at the University of Pittsburgh Medical Center
between January 1, 1998 and June 30, 2003. To be included as
a case, patients had to be ≥18 years of age, hospitalized for >24
hours, have a hemoglobin (Hgb) test during their stay, and expe-
rience an in-hospital fall. Control patients were matched 1 :1 on
age, gender, race, service, length of stay (±one day), and year of
admission. Anemia was assessed using the ﬁrst Hgb value and
deﬁned as Hgb < 12g/dL for females or Hgb < 13g/dL for males.
A reference fall date was calculated for each control patient by
using the same timeframe (e.g. days to fall) as its matched fall
case. Drug utilization was identiﬁed two-days before the fall date
for cases and the reference fall date for controls. Statistics per-
formed were T-tests, chi-square, and logistic regression using
“fall” as the dependent variable and comorbidities, drug class,
and anemia status as covariates. RESULTS: There were a total
of 1248 patients identiﬁed for study. The mean age was 68 ± 15
years, 49% were female, and 89% were Caucasian. Cases were
more likely to have congestive heart failure (23% vs. 19%),
chronic kidney disease–CKD (12% vs. 7%), and diabetes (29%
vs. 23%) and be receiving antidepressants (27% vs. 21%), ben-
zodiazepines (30% vs. 24%), and anticonvulsants (22% vs.
15%). Regression analysis demonstrated that patients with CKD
(OR = 1.8, p = 0.003), pneumonia (OR = 1.6, p = 0.03), and
those receiving antidepressants (OR = 1.3, p = 0.02), benzodi-
azepines (OR = 1.4, p = 0.007), and anticonvulsants (OR = 1.5,
p = 0.006) were more likely to experience an in-hospital fall.
CONCLUSION: In this case-control study, anemia did not con-
tribute to in-hospital falls.
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OBJECTIVES: The objectives of this study were to describe the
characteristics of patients experiencing in-hospital falls, to iden-
tify the prevalence of anemia, and to evaluate whether anemia
contributes to longer length of stay. METHODS: A retrospective
study of patients experiencing an in-hospital fall between
January 1, 1998 and June 30, 2003 was conducted at the Uni-
versity of Pittsburgh Medical Center. To be included, patients
had to be ≥18 years of age, admitted into the hospital for >24
hours, and have a hemoglobin (Hgb) test during their stay.
Demographics, comorbidities, Hgb tests, and drug groups were
extracted from a medical record data repository. Anemia was
assessed using the last Hgb value prior to the fall date and
deﬁned as Hgb < 12g/dL for females or Hgb < 13g/dL for males.
Statistics included T-tests, chi-square, and a linear regression
analysis using length of stay (log transformed) after the fall 
date as the dependent variable and demographics, comorbidities,
drug class, and anemia status as independent variables.
RESULTS: There were 1518 patients that met study criteria. 
The mean age was 65 ± 16 years, 49% were female, 81% were
Caucasian, and 79% were anemic. Most patients (60%) fell
within one week of hospital admission. Anemic patients were
more likely to have chronic kidney disease (8% vs. 4%) and gas-
trointestinal diseases (20% vs. 8%). Drug utilization was similar
except that anemic patients were less likely to receive anticon-
vulsants (20% vs. 26%). A linear regression analysis showed 
that patients who were younger (p = 0.01), had cardiac arrhyth-
mias (p < 0.001), pneumonia (p < 0.001), and gastrointestinal
disease (p < 0.001) and those receiving antihistamines (p = 0.02)
were more likely to have longer lengths of stay. CONCLUSION:
The majority of patients experiencing an in-hospital fall were
anemic, however, anemia did not contribute to increased length
of stay.
